Mesenchymal stem cell administration at coronary artery reperfusion in the rat by two delivery routes: a quantitative assessment
- PMID: 18755200
- PMCID: PMC2582905
- DOI: 10.1016/j.lfs.2008.07.020
Mesenchymal stem cell administration at coronary artery reperfusion in the rat by two delivery routes: a quantitative assessment
Abstract
Aims: Ideally, mesenchymal stem cells (MSC) home to and/or remain at the site of damaged myocardium when administered after myocardial infarction. However, MSC may not remain in the heart, but instead relocate to other areas. We investigated quantitatively the distribution of labeled rat MSC, given by two routes after coronary artery occlusion/reperfusion in rats.
Main methods: Rats were subjected to 45 min of coronary artery occlusion and 7 days of reperfusion. Before reperfusion rats received 2 x 10(6) MSC, labeled with europium, injected directly into the ischemic region of the heart (n = 9) or intravenously (n = 8). After 1 week tissues were analyzed for label content together with a standard curve of known quantities of labeled MSC.
Key findings: In rats receiving cells injected directly into the myocardium, 15% of labeled cells were retained in the heart. When the cells were administered intravenously, no MSC were detected in the heart. The route of administration did not affect distribution to other organs, as the number of MSC in liver, spleen and lung was similar with both routes of delivery.
Significance: Even with direct intramyocardial injection, only a small proportion of the cells are retained in the heart, instead traveling to other organs. With intravenous injection there was no evidence that cells "homed" to the damaged heart. Although cell delivery to the heart was significantly affected by the route of administration, the distribution of cells to other organs was similar with both routes of administration.
Figures


References
-
- Barbash IM, Chouraqui P, Baron J, et al. Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarct myocardium. Feasibility, cell migration, and body distribution. Circulation. 2003;108:863–868. - PubMed
-
- Chin BB, Makamoto Y, Bulte JW, Pittenger MF, Wahi R, Kratchman DL. 111In oxine labeled mesenchymal stem cell SPECT after intravenous administration in myocardial infarction. Nuclear Medicine Communications. 2003;24:21149–21154. - PubMed
-
- Dai W, Hale SL, Martin BJ, et al. Allogeneic mesenchymal stem cell transplantation in postinfarcted rat myocardium. Short- and long-term effects. Circulation. 2005;112:214–223. - PubMed
-
- Dai W, Hale SL, Kloner RA. Role of paracrine action of mesenchymal stem cells in the improvement of left ventricular function after coronary artery occlusion in rats. Regenerative Medicine. 2007;2:63–68. - PubMed
-
- Dow JS, Simkhovich BZ, Kedes L, Kloner RA. Washout of transplanted cells from the heart: A potential new hurdle for cell transplantation therapy. Cardiovascular Research. 2005;67:301–307. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical